TECHNOLOGY SUMMARY

Targeted drug is common in cancer therapy. Immuno-oncology drugs only effect in 10-25％ cancers. CAR-T tumor immunotherapies only treat small number leukemias. Drug resistances may occur post-therapy: Some patients innately don't respond to a targeted drug in initial treatment; Tumor may develop resistance against an initial effective drug post-0.6-2 years. Drug resistances are often detected too late and cause mortality with CT scan 3 months post-therapy. About 60% drug resistances are not relative to current known oncogene, undetectable by liquid biopsy (ctDNA, CTC, exosome gene assay); their results often false-negative. Current liquid biopsy delay disease treatments, since presence of CTC or ctDNA indicate resistant tumors had metastasized earlier. By directly assaying serum biomarker downstream of oncoproteins that targeted drugs are acting, clinical trials showed our liquid biopsy IVD kit early (2-weeks post-therapy) and “truly” real-time monitor therapy resistance of most drugs and most cancer types, solve problems of CT, liquid biopsy in detecting resistance, help patients get correct drug in time. Our product can facilitate precision medicine; help CT and liquid biopsy get real-time monitoring resistance ability, save cancer treatment expenses.

AREA/MATURITY/AWARDS

Primary Application Area: Biotech, Pharma

Technology Development Status: Ready to Market

Technology Readiness Level: TRL 9

Vetted Programs/Awards: 2014, 2016, selected for the Ministry of Science and Technology Innovation and Entrepreneurship Competition.
2016 Ministry of Economic Affairs SBIR Program Grant
2014, Gold Award, Taipei International Invention and competition.
2016, Silver Award, the National Invention Award.

SHOWCASE SUMMARY

Organization Type: Mid-stage Startup (A or B)

Showcase Booth #: 10M

GOVT/EXTERNAL FUNDING SOURCES

External Funding to Date: NONE